GSK plc (FRA:GS71)
Germany · Delayed Price · Currency is EUR | Market Cap | 94.09B +28.8% |
| Revenue (ttm) | 37.45B +4.1% |
| Net Income | 6.55B +122.0% |
| EPS | 1.59 +123.2% |
| Shares Out | n/a |
| PE Ratio | 14.36 |
| Forward PE | 11.38 |
| Dividend | 0.76 (3.22%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 340 |
| Average Volume | 759 |
| Open | 23.59 |
| Previous Close | 23.60 |
| Day's Range | 23.59 - 23.69 |
| 52-Week Range | 14.68 - 26.02 |
| Beta | n/a |
| RSI | 41.49 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
Amgen (AMGN) and GSK (GSK) Expand Reach with TrumpRx Partnership
Amgen (AMGN) and GSK (GSK) Expand Reach with TrumpRx Partnership
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults
On Friday, the U.S. Food and Drug Administration (FDA) expanded the approved age indication for GSK plc’s (NYSE: GSK) respiratory syncytial virus vaccine, Arexvy. The approval allows its use in adult...
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.
GSK Says FDA Expands Arexvy RSV Vaccine Approved Age To Adults 18 To 49 Years At Increased Risk
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration or FDA, has expanded the approved age indication of Arexvy (Respiratory Syncytial Virus va...
GSK gets US FDA approval for expanded use of RSV vaccine
British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 wh...
BioVersys Doses First Patient In Phase 2b Of AlpE
(RTTNews) - BioVersys AG (BIOV) has announced that the first patient has been dosed in its Phase 2b clinical trial of AlpE for pulmonary tuberculosis, marking a key milestone in the company's collabor...
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency
FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency
FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder
The Food and Drug Administration approved leucovorin, a drug the Trump administration has touted as a potential therapy for autism, to treat cerebral folate transport deficiency, a neurological disord...
FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year
The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral folate deficiency on Tuesday—but stopped short of approving it as a treatment for ...
US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms
WASHINGTON, March 10 (Reuters) - The U.S. FDA on Tuesday approved leucovorin, a decades-old generic drug, for use against an ultra-rare disorder called cerebral folate deficiency, but not for childre...
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
The Food and Drug Administration approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn
UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of drugs to fight superbugs remains “worryingly thin” and ...
Former GlaxoSmithKline HQ in west London to be transformed into 1,500 new homes
Ambitious plans to redevelop the former headquarters of GlaxoSmithKline in Brentford have been given the green light
GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
GSK: Alfasigma To Acquire Rights To Develop, Manufacture, Commercialise Linerixibat
(RTTNews) - GSK plc (GSK, GSK.L) and Alfasigma announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an inv...
GSK licenses liver disease drug to Italy's Alfasigma
GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma for an upfront payment o...
Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m
Erginbilgic, pictured, has led a stunning turnaround, and has been rewarded with a deal that puts him on course to rival AstraZeneca chief Pascal Soriot.
Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss
Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise Business live – latest updates GSK awarded Emma Walmsley a near-50% pay rise to £15.6m in ...
SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline
(RTTNews) - SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on it...
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Ph...
Price Over Earnings Overview: GSK
Looking into the current session, GSK Inc. (NYSE: GSK) shares are trading at $57.03, after a 0.76% drop. Over the past month, the stock fell by 1.03% , but over the past year, it actually spiked by 4...
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Off Plan
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Off Plan
GSK PLC (GSK) Shares Gap Down to $56.525 on Mar 3
GSK PLC (GSK) Shares Gap Down to $56.525 on Mar 3